Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interleukin-12 (IL-12) plasmid DNA is a genetic adjuvant developed by the National Institute of Allergy and Infectious Diseases (NIAID) for use in therapeutic and preventive HIV vaccine regimens. It consists of a circular DNA plasmid containing the genes for human IL-12 (p35 and p40 subunits). When administered, typically via intramuscular injection followed by in vivo electroporation, the plasmid enters host cells which then express and secrete the IL-12 cytokine. IL-12 acts as a potent immunomodulator that enhances the magnitude and quality of cellular immune responses, particularly Th1-type T-cell responses, against co-administered HIV antigens (such as those in the HIV-MAG DNA vaccine).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on interleukin-12 plasmid DNA.